First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Luis Paz‐Ares , Tudor‐Eliade Ciuleanu , Manuel Cobo +24 more 2021 The Lancet Oncology 1273 citations